Synapse - David Solit

Results (783)

FLT PET as a non-invasive marker of response to MEK inhibition

Meeting Abstract

Solit, D. B.; Santos, E.; Pratilas, C. A.; Moroz, M.; Blasberg, R.; Sebolt-Leopold, J.; Larson, S.; Rosen, N.
Cancer Research (2006)

Fulltext@MSK | Save

Genetic and pharmacological inhibition of P13 kinase signaling in vivo sensitizes tumors to EGFR inhibitors and to taxol

Meeting Abstract

She, Q. B.; Ye, Q.; She, Y.; Solit, D. B.; Rosen, N.
Cancer Research (2006)

Fulltext@MSK | Save

MAPK activation by B-RAF mutation or tyrosine kinase activation is associated with different patterns of feedback regulation that correlate with functional output of the pathway

Meeting Abstract

Pratilas, C. A.; Grbovic, O.; Sebolt-Leopold, J.; Rosen, N.; Solit, D. B.
Cancer Research (2006)

Fulltext@MSK | Save

IGF-1 rescues rapamycin-induced cell growth inhibition

Meeting Abstract

O'reilly, K. E.; She, Q. B.; Solit, D. B.; Rosen, N.
Cancer Research (2006)

Fulltext@MSK | Save

Phase I dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T)

Meeting Abstract

Modi, S.; Stopeck, A. T.; Gordon, M. S.; Solit, D.; Bagatell, R.; Ma, W.; Wheler, J.; Cropp, G. F.; Rosen, N.; Johnson, R. G. Jr; more...
Cancer Research (2006)

Fulltext@MSK | Save

Combined inhibition of PI3K/AKT and MAPK signaling is required to inhibit translational initiation and to induce apoptosis in human tumors

Meeting Abstract

She, Q. B.; Ye, Q.; Solit, D.; Rosen, N.
EJC Supplements (2006)

Fulltext@MSK | Save

Inhibition of Hsp90 function downregulates EGFR and sensitizes EGFR-mutant xenografts to paclitaxel

Meeting Abstract

Sawai, A.; Greulich, H.; Ye, Q.; Sellers, W.; Rosen, N.; Solit, D.
EJC Supplements (2006)

Fulltext@MSK | Save

B-RAF mutation is associated with altered patterns of negative feedback of MAPK signaling that correlate with increased output of the pathway and increased sensitivity to MEK inhibition

Meeting Abstract

Pratilas, C.; Grbovic, O.; Zhao, H.; Viale, A.; Solit, D.; Rosen, N.
EJC Supplements (2006)

Fulltext@MSK | Save

Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with Her2-positive breast cancer: Preliminary results

Meeting Abstract

Modi, S.; Stopeck, A.; Linden, H. M.; Sugarman, S.; Ma, W.; Solit, D.; Rosen, N.; Kersey, K.; Johnson, R. G.; Hannah, A. L.; more...
Breast Cancer Research and Treatment (2006)

Fulltext@MSK | Save

Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T)

Meeting Abstract

Modi, S.; Stopeck, A.; Gordon, M. S.; Solit, D.; Ma, W.; Wheler, J.; Cropp, G.; Johnson, R. G.; Hannah, A. L.; Hudis, C.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save